| pubmed-article:8932983 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8932983 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:8932983 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:8932983 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
| pubmed-article:8932983 | lifeskim:mentions | umls-concept:C0005821 | lld:lifeskim |
| pubmed-article:8932983 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
| pubmed-article:8932983 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8932983 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8932983 | pubmed:dateCreated | 1997-2-28 | lld:pubmed |
| pubmed-article:8932983 | pubmed:abstractText | Platelet numbers and circulating haemopoietic progenitor cells were examined in 12 patients with advanced malignancies who were receiving recombinant human interleukin-6 (rhIL-6) as part of an investigation of its thrombopoietic effects. Patients received recombinant glycosylated IL-6 by daily subcutaneous injection for 7 consecutive days in doses of 1, 3 or 10 micrograms/kg/day. Platelet numbers increased reaching a peak on days 12-15 with a mean on day 15 of 198.1% of pre-treatment values. This was accompanied by a significant fall in the mean platelet volume (mean decrease of 10.6%, P = 0.0044). No significant correlation was seen between the IL-6 dose and the change in platelet number. No significant differences were observed between pre- and post-treatment levels of circulating erythroid burst-forming units (E-BFU) and granulocyte macrophage colony-forming units (GM-CFU) but a small significant increase was seen in circulating primitive progenitor cells measured in a plastic-adherent (P delta) assay (P = 0.025). As positive controls, a group of patients treated with cyclophosphamide/G-CSF showed significant increases in GM-CFU (P = 0.018), E-BFU (P = 0.018) and P delta progenitors (P = 0.028). These data suggest that the thrombopoietic effects of IL-6 are mediated at a relatively late stage via effects on megakaryocyte differentiation, with a relatively small effect on circulating haemopoietic progenitors. | lld:pubmed |
| pubmed-article:8932983 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8932983 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8932983 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8932983 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8932983 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8932983 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8932983 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8932983 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8932983 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8932983 | pubmed:issn | 1043-4666 | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:JohnsonRR | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:GordonM YMY | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:MorganGG | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:SelbyP JPJ | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:ClarkeDD | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:JohnsonP WPW | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:StormJJ | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:KinseyS ESE | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:BanksR ERE | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:IllingworthJ... | lld:pubmed |
| pubmed-article:8932983 | pubmed:author | pubmed-author:PerrenT JTJ | lld:pubmed |
| pubmed-article:8932983 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8932983 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:8932983 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8932983 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8932983 | pubmed:pagination | 717-23 | lld:pubmed |
| pubmed-article:8932983 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:meshHeading | pubmed-meshheading:8932983-... | lld:pubmed |
| pubmed-article:8932983 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8932983 | pubmed:articleTitle | Effects of interleukin 6 administration on platelets and haemopoietic progenitor cells in peripheral blood. | lld:pubmed |
| pubmed-article:8932983 | pubmed:affiliation | Imperial Cancer Research Fund, Cancer Medicine Research Fund, St James's University Hospital, Leeds, UK. | lld:pubmed |
| pubmed-article:8932983 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8932983 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8932983 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:8932983 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:8932983 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:8932983 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8932983 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8932983 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8932983 | lld:pubmed |
